TRAVERSA SERGIO 4
4 · RELMADA THERAPEUTICS, INC. · Filed Dec 16, 2025
Insider Transaction Report
Form 4
TRAVERSA SERGIO
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2025-12-15$4.12/sh+27,500$113,300→ 1,300,000 total - Award
Stock Appreciation Rights
2025-12-12+1,198,000→ 1,198,000 totalExercise: $4.06From: 2026-03-12Exp: 2035-12-12→ Common Stock (1,198,000 underlying)
Footnotes (3)
- [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- [F2]Purchase prices range from $4.10 to $4.12 per share, inclusive.
- [F3]The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.